The global Fuchs endothelial corneal dystrophy (FECD) market garnered a market value of US$ 180 Billion in 2023 and is expected to accumulate a market value of US$ 370 Billion by registering a CAGR of 7.5% in the forecast period 2023-2033. The expanding worldwide aging population, as well as increased awareness of eye illnesses and corneal donation, is likely to boost the market. Furthermore, increased research interest in cellular treatment techniques is expected to generate significant potential for the Industry in the coming years.
The increased incidence of diabetes throughout the world will be a primary driver, resulting in an increase in the market's growth rate. According to the American Optometric Association, approximately 7 million people in the United States have undiagnosed diabetes, with 12,000 to 24,000 people losing their sight each year. Diabetic retinopathy is the leading cause of blindness in the United States today. Diabetic individuals must get a dilated eye exam once a year. By keeping a watch out for retinal anomalies, diabetic issues such as blindness and other consequences can be prevented.
In addition, the occurrence of different diseases such as cataracts, glaucoma, and age-related macular degeneration will drive market expansion. The growing healthcare spending, which aids in the improvement of its infrastructure, is a crucial element driving the growth rate of the market. Furthermore, numerous government organizations intend to improve healthcare infrastructure by boosting financing, which would have an impact on market dynamics.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 180 Billion |
| Anticipated Forecast Value (2033) | US$ 370 Billion |
| Projected Growth Rate (2023 to 2033) | 7.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for Fuchs Endothelial Corneal Dystrophy (FECD) is projected to increase at a CAGR of 7.5% during the forecast period between 2023 and 2033, reaching a total of US$ 370 Billion in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6%.
The growing elderly population is expected to boost the market's growth rate. According to the World Ageing 2020 projection, there will be 727 million individuals aged 65 and over in 2020. This population is predicted to reach 1.5 billion by 2050. The proportion of the population aged 65 and older is expected to climb from 9.3% in 2020 to around 16.0% in 2050. The geriatric population is predicted to expand, and this group will require housing.
Furthermore, the growing number of government activities to raise awareness and change people's sedentary lifestyles will result in the rise of the market. Along with this, increased disposable income and expanding government-friendly programs would boost the market’s growth. The market's expansion is being propelled by an increase in the number of Research and Development activities. This would create advantageous prospects for the expansion of the market. Novel entrants are concentrating their efforts on developing new steroid-based formulations to treat dry eye syndrome (DES), which is also a key driving factor in the market.
Expanding Worldwide Ageing Population to Improve Maintenance and Performance
The expanding worldwide ageing population, as well as increased awareness of eye illnesses and corneal donation, are likely to boost the market. Population growth and ageing are likely to drive up demand for eye care in the coming years. With the world's ageing population, the demand for corneal transplantation is expected to climb dramatically throughout the anticipated period.
Furthermore, researchers throughout the world are studying and developing novel technologies to guarantee the prompt treatment of individuals with Fuchs endothelial corneal dystrophy (FECD). Rising cellular therapy research activity is expected to generate significant prospects for the global market in the coming years.
Principal Consultant
Dangers Associated with Surgical Intervention to Slow Down the Market Growth
The dangers associated with surgical intervention, as well as a scarcity of donor grafts, may have an impact on market growth.
Progressive Acceptance of Upgraded Technology to Widen Profit Margins
Asian nations are predicted to develop the quickest due to rising awareness, enhanced personal care and cleanliness, increased diagnostic rates, progressive acceptance of upgraded technology, rising disposable income, and burgeoning healthcare infrastructures. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023 to 2033.
Greater Healthcare Knowledge to Accelerate the Market
Because of greater healthcare knowledge, illness incidence, and a high rate of diagnosis, North America was found to have the highest share of the market.
In this multi-screen universe, individuals of all ages may be found. Computer or digital screen usage may result in less blinking, which may add to symptoms of Fuchs Endothelial Corneal Dystrophy (FECD), hence boosting the need for better and more effective Fuchs Endothelial Corneal Dystrophy (FECD) therapies, which is projected to stimulate growth in the North American region analyzed.
Furthermore, the region's expanding elderly population is driving market expansion since they are more susceptible to numerous ocular ailments such as Fuchs Endothelial Corneal Dystrophy (FECD). North America is expected to grow at a CAGR of 7.4% in the assessment period 2023 to 2033.
Increased Research and Development to Drive the Market Growth
With increased research and development, Europe is providing the second-highest share of the Fuchs endothelial corneal dystrophy (FECD) market. Europe is the leading market for corneal transplants, and it will continue to grow in the near future due to the availability of various treatment options and prevention strategies, as well as the growing influence of organ donation programs and growing government focus on organ donation policies. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Hospitals Segment to enhance Sales Prospects
The Fuchs Endothelial Corneal Dystrophy (FECD) market is divided into three segments based on end-users: hospitals, ASCS, and others. The hospital's segment accounts for the majority of the worldwide market.
Key start-up players in the Fuchs Endothelial Corneal Dystrophy (FECD) are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key Fuchs Endothelial Corneal Dystrophy (FECD) start-ups are as follows:
The market for Fuchs Endothelial Corneal Dystrophy (FECD) is moderately competitive. With regard to market share, the industry is currently dominated by a few significant competitors. With the growing senior population and high illness incidence, a few new smaller competitors are projected to enter the industry in the next years.
Key players in the Fuchs endothelial corneal dystrophy market are Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, Emmecell, Santen, AJL Ophthalmic SA, Massachusetts Eye, and Ear, KeraMed, Inc, and Presbia Plc.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 180 Billion |
| Market Value in 2033 | US$ 370 Billion |
| Growth Rate | CAGR of 7.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US Billion and CAGR from 2023-2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to expand at a 7.5% value CAGR by 2033
The global Fuchs Endothelial Corneal Dystrophy (FECD) market is estimated at a market value of US$ 180 Billion
The global Fuchs Endothelial Corneal Dystrophy (FECD) is expected to garner a market value of US$ 370 Billion
As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023 to 2033.
Key players in the Fuchs Endothelial Corneal Dystrophy (FECD) market are Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, Emmecell, Santen, AJL Ophthalmic SA, Massachusetts Eye, and Ear, KeraMed, Inc and Presbia Plc.
North America is expected to grow at a CAGR of 7.4% in the assessment period 2023 to 2033.
Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023 to 2033.
The hospitals segment is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) in the forecast period 2023-2033.
1. Executive Summary | Fuchs Endothelial Corneal Dystrophy (FECD) Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Phototherapeutic Keratectomy
5.3.2. AMillioniotic Membrane Transplants
5.3.3. Anterior Stromal Puncture
5.3.4. Conjunctival Flaps
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033
6.3.1. Slit-lamp Examination
6.3.2. Molecular Genetic Tests
6.3.3. Pachymetry
6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users , 2023 to 2033
7.3.1. Hospitals
7.3.2. ASCs
7.3.3. Others
7.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. Asia-Pacific
8.3.6. Middle East & Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The US
9.2.1.2. Canada
9.2.2. By Treatment
9.2.3. By Diagnosis
9.2.4. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By Diagnosis
9.3.4. By End Users
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Treatment
10.2.3. By Diagnosis
10.2.4. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By Diagnosis
10.3.4. By End Users
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Benelux
11.2.1.2. France
11.2.1.3. Germany
11.2.1.4. Italy
11.2.1.5. Nordic
11.2.1.6. Spain
11.2.1.7. The UK
11.2.1.8. Rest of Western Europe
11.2.2. By Treatment
11.2.3. By Diagnosis
11.2.4. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By Diagnosis
11.3.4. By End Users
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Rest of Eastern Europe
12.2.2. By Treatment
12.2.3. By Diagnosis
12.2.4. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By Diagnosis
12.3.4. By End Users
12.4. Key Takeaways
13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Australia
13.2.1.6. New Zealand
13.2.1.7. Rest of APAC
13.2.2. By Treatment
13.2.3. By Diagnosis
13.2.4. By End Users
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment
13.3.3. By Diagnosis
13.3.4. By End Users
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Treatment
14.2.3. By Diagnosis
14.2.4. By End Users
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment
14.3.3. By Diagnosis
14.3.4. By End Users
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. The US
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment
15.1.2.2. By Diagnosis
15.1.2.3. By End Users
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment
15.2.2.2. By Diagnosis
15.2.2.3. By End Users
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment
15.3.2.2. By Diagnosis
15.3.2.3. By End Users
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment
15.4.2.2. By Diagnosis
15.4.2.3. By End Users
15.5. Benelux
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment
15.5.2.2. By Diagnosis
15.5.2.3. By End Users
15.6. France
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment
15.6.2.2. By Diagnosis
15.6.2.3. By End Users
15.7. Germany
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment
15.7.2.2. By Diagnosis
15.7.2.3. By End Users
15.8. Italy
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment
15.8.2.2. By Diagnosis
15.8.2.3. By End Users
15.9. Nordic
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment
15.9.2.2. By Diagnosis
15.9.2.3. By End Users
15.10. Spain
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment
15.10.2.2. By Diagnosis
15.10.2.3. By End Users
15.11. The UK
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment
15.11.2.2. By Diagnosis
15.11.2.3. By End Users
15.12. Poland
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment
15.12.2.2. By Diagnosis
15.12.2.3. By End Users
15.13. Russia
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment
15.13.2.2. By Diagnosis
15.13.2.3. By End Users
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment
15.14.2.2. By Diagnosis
15.14.2.3. By End Users
15.15. Malaysia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment
15.15.2.2. By Diagnosis
15.15.2.3. By End Users
15.16. Singapore
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment
15.16.2.2. By Diagnosis
15.16.2.3. By End Users
15.17. Thailand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment
15.17.2.2. By Diagnosis
15.17.2.3. By End Users
15.18. Australia
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment
15.18.2.2. By Diagnosis
15.18.2.3. By End Users
15.19. New Zealand
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment
15.19.2.2. By Diagnosis
15.19.2.3. By End Users
15.20. GCC Countries
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment
15.20.2.2. By Diagnosis
15.20.2.3. By End Users
15.21. South Africa
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment
15.21.2.2. By Diagnosis
15.21.2.3. By End Users
15.22. Israel
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Treatment
15.22.2.2. By Diagnosis
15.22.2.3. By End Users
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment
16.3.3. By Diagnosis
16.3.4. By End Users
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Kowa Pharmaceuticals
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Trefoil Therapeutics
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Alcon
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Emmecell
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Santen
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. AJL Ophthalmic SA
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Massachusetts Eye and Ear
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Alcon, Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. KeraMed, Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Presbia Plc
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Fuchs Endothelial Corneal Dystrophy (FECD) Market
